SCHEMBL5318944

SCHEMBL5318944

CN1C[C@@H](O)[C@H](O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL85474 1.00
SCHEMBL16855025 1.00
SCHEMBL1971264 1.00
SCHEMBL3436779 1.00
SCHEMBL3379916 0.86 GLB1 (0.48)
SCHEMBL14426713 0.86 GAA (0.48)
SCHEMBL15599042 0.86 GLB1 (0.48)
SCHEMBL14426706 0.86 GAA (0.48)
SCHEMBL14426708 0.86 GAA (0.48)
SCHEMBL9710932 0.86 GLB1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5872249-A QUATERNIZATION, SALT FORMATION, AMINATION, DEALKYLATION KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 1999-02-16 US claimed
US-5675003-A ACTIVITY AGAINST STAPHYLOCOCCUS, ENTEROBACTER KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 1997-10-07 US claimed
CN-118317944-A Acyclic lipids and methods of use thereof 雷纳嘉德医疗管理公司 2024-07-09 CN disclosed
CN-118234707-A Cyclic lipids and methods of use thereof 雷纳嘉德医疗管理公司 2024-06-21 CN disclosed
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. 2023-09-14 US disclosed
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. 2023-09-14 US disclosed
EP-4097092-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING Protego Biopharma, Inc. (US) 2022-12-07 EP disclosed
CN-115298168-A Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding 普罗泰格生物制药公司 2022-11-04 CN disclosed
EP-3746435-B1 SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER (US) 2022-08-03 EP disclosed
EP-3746435-B1 SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER (US) 2022-08-03 EP disclosed
US-20210292330-A1 PYRROLIDINE-FUSED HETEROCYCLES ERASCA, INC. 2021-09-23 US disclosed
WO-2007121918-A2 USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2007-11-01 WO disclosed
WO-2007096740-A2 NOVEL CEPHALOSPORINS ORCHID RESEARCH LABORATORIES LIMITED (IN) 2007-08-30 WO disclosed
EP-1643998-B1 DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA HOFFMANN LA ROCHE (CH) 2007-08-29 EP disclosed
US-5872249-A QUATERNIZATION, SALT FORMATION, AMINATION, DEALKYLATION KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 1999-02-16 US disclosed
US-5872249-A QUATERNIZATION, SALT FORMATION, AMINATION, DEALKYLATION KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 1999-02-16 US disclosed
US-5675003-A ACTIVITY AGAINST STAPHYLOCOCCUS, ENTEROBACTER KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 1997-10-07 US disclosed
US-5675003-A ACTIVITY AGAINST STAPHYLOCOCCUS, ENTEROBACTER KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 1997-10-07 US disclosed
US-5571909-A ANTIBIOTICS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 1996-11-05 US disclosed
US-5571909-A ANTIBIOTICS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 1996-11-05 US disclosed